Get access to our best features

Get access to our best features

Published 3 years ago

StrataTech gains FDA approval for 'novel' skin substitute to treat burns

Summary by Ground News

StrataTech, owned by the U.K. pharmaceutical company Mallinckrodt, got the greenlight for StrataGraft from the FDA based on a promising phase three clinical study. Results showed 96% of patients did not need a donor tissue harvest to heal second-degree burn wounds. A majority of patients’ wounds healed completely in the study, and there were no reports that the treatment was rejected.

0 Articles

0 Articles

All

Left

Center

Right

Wisconsin State Journal

StrataTech gains FDA approval for 'novel' skin substitute to treat burns

"This type of technology has great potential for burn patients," said Angela Gibson, the UW Health medical director of wound healing services.

3 years ago·Madison, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated3 years agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Wisconsin State Journal

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

Trending Topics

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc.